Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study

[1]  T. Harada,et al.  Incidence of opioid‐induced constipation in Japanese patients with cancer pain: A prospective observational cohort study , 2019, Cancer medicine.

[2]  Xiaoyu Qu,et al.  A meta-analysis of naldemedine for the treatment of opioid-induced constipation , 2019, Expert review of clinical pharmacology.

[3]  M. Camilleri,et al.  Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. , 2018, The lancet. Gastroenterology & hepatology.

[4]  J. A. Arjona Ferreira,et al.  Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers , 2018, Clinical pharmacology in drug development.

[5]  M. Tsutsumi,et al.  Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Agah,et al.  Reliability and validity of the Persian version of patient assessment of constipation- quality of life (PAC-QOL) questionnaire , 2017, Gastroenterology and hepatology from bed to bench.

[7]  D. Cohen,et al.  Publisher's Note , 2017, Neuroscience & Biobehavioral Reviews.

[8]  L. Webster,et al.  A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain , 2017, Pain medicine.

[9]  C. Marcassa,et al.  Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis , 2015, Drug design, development and therapy.

[10]  A. Drewes,et al.  Evolving paradigms in the treatment of opioid-induced bowel dysfunction , 2015, Therapeutic advances in gastroenterology.

[11]  K. E. Clemens,et al.  Quality of Life and Healthcare Resource in Patients Receiving Opioids for Chronic Pain: A Review of the Place of Oxycodone/Naloxone , 2014, Clinical Drug Investigation.

[12]  G. Becker,et al.  Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid‐induced constipation , 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[13]  P. Gisondi,et al.  Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study , 2013, The British journal of dermatology.

[14]  Y. Itoh,et al.  A Multi-institutional Study Analyzing Effect of Prophylactic Medication for Prevention of Opioid-induced Gastrointestinal Dysfunction , 2012, The Clinical journal of pain.

[15]  P. Stone,et al.  Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. , 2012, The Lancet. Oncology.

[16]  M. Camilleri,et al.  Opioid-Induced Constipation: Challenges and Therapeutic Opportunities , 2011, The American Journal of Gastroenterology.

[17]  A. Sabato,et al.  Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. , 2010, European review for medical and pharmacological sciences.

[18]  Kenji Ikeda,et al.  Reduction of opioid side effects by prophylactic measures of palliative care team may result in improved quality of life. , 2010, Journal of palliative medicine.

[19]  A. Lipman,et al.  Opioid‐induced bowel disorders and narcotic bowel syndrome in patients with chronic non‐cancer pain , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[20]  N. Schaefer,et al.  Gastrointestinal symptoms under opioid therapy: A prospective comparison of oral sustained‐release hydromorphone, transdermal fentanyl, and transdermal buprenorphine , 2009, European journal of pain.

[21]  Christine Miaskowski,et al.  The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). , 2009, Pain medicine.

[22]  S. Fehnel,et al.  Gastrointestinal side effects in chronic opioid users: results from a population‐based survey , 2008, Alimentary pharmacology & therapeutics.

[23]  S. Wilkinson,et al.  Laxatives for the management of constipation in palliative care patients. , 2006, The Cochrane database of systematic reviews.

[24]  O. Chassany,et al.  Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire , 2005, Scandinavian journal of gastroenterology.

[25]  P. Higgins,et al.  Epidemiology of Constipation in North America: A Systematic Review , 2004, American Journal of Gastroenterology.

[26]  A. Sacristan,et al.  Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. , 1998, Journal of pain and symptom management.